Medical device start-up Topera Medical closed a $25 million funding round, according to federal Securities & Exchange Commission filings.
The San Diego, Calif.-based startup, which came out of stealth mode at the Heart Rhythm Society meeting last year, has FDA 510(k) clearance for its RhythmView 3D mapping system, which treats patients with cardiac rhythm disorders by targeting treatment on electrical "hot spots" in the heart.
The company closed the recent round on Friday, March 15th. The names of the investors were not listed on the filing.
Last July, Topera released results from its Confirm trial in which researchers said they were able to "shut down atrial fibrillation or very significantly slowed it in 86% of patients in an average of only 2.5 minutes," according to a press release.
That compared with conventional treatment which delivers ablation to a larger region of the heart, which takes longer and "often did not shut down atrial fibrillation."
After 2 years, patients treated with the new targeting methods exhibited 82.4% freedom from AF episodes, compared with 44.9% freedom among patients who received the conventional therapy.
Topera Medical originally unveiled the highly anticipated results of its Confirm study at the Heart Rhythm Society’s annual meeting in Boston in May, touting a 100% success rate.